AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18165589
Drug: Nicotine 3
RxNorm normalized name: Nicotine 312.5 microgram/hour prolonged-release transdermal patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine 3 mg
Trial: 12646431
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of contrast material plus a 50‐mL saline chaser
Trial: 12646431
Drug: 150 mL
RxNorm normalized name: REBYOTA 150 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mL of contrast material
Trial: 9350881
Drug: Plantain flour‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plantain flour‐based solution (Group B)
Trial: 8411742
Drug: Propranolol (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (dose reducing heart rate by 25%)
Trial: 8411742
Drug: Sclerotherapy (intra‐variceal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sclerotherapy (intra‐variceal and extra‐variceal injection of ethanolamine oleate)
Trial: 25748876
Drug: Direct referral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct referral to low-dose chest CT (LDCT)
Trial: 18637080
Drug: IV butorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV butorphanol (1 mg)
Trial: 22411639
Drug: IV ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketorolac (30 mg)
Trial: 11739221
Drug: Clinical medication
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical medication review by a pharmacist
Trial: 12969084
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg administered through a nasogastric tube
Trial: 12969084
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg administered orally as an intact capsule
Trial: 8884304
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg/day for 7 days, Tinidazole 500 mg bid for 7 days, Clarithromycin 250 mg bid for 7 days (Group A)
Trial: 8884304
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg bid for 14 days, Amoxycillin 1000 mg bid for 14 days (Group B)
Trial: 4001769
Drug: Mebendazole 2
RxNorm normalized name: mebendazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole 2 G per day for 14 days preceded by 300 mg of levamisole in 2 doses
Trial: 4001769
Drug: Placebo vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vitamin tablets for 14 days
Trial: 29614378
Drug: Exposure-based internet-delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based internet-delivered cognitive behavior therapy (Internet-CBT)
Trial: 29303212
Drug: Topical silicone
RxNorm normalized name: silicones Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical silicone gel
Trial: 20657532
Drug: Topical heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical heparin spray (added to antiplatelet therapy)
Trial: 20657532
Drug: Antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy only
Trial: 11126694
Drug: Estradiol patch
RxNorm normalized name: Estradiol Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol patch
Trial: 9091475
Drug: Interferon gamma
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon gamma (IFN‐gamma) 100 micrograms subcutaneously for 5 consecutive days followed by 100 micrograms once weekly for 4 weeks
Trial: 7690364
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (TE) 300 mg im, each week for 6 weeks
Trial: 7690364
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (ND) 300 mg im, each week for 6 weeks
Trial: 30324422
Drug: Phase III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase III formulation with reduced SLS content, administered following a low-fat meal
Trial: 30324422
Drug: Phase I/II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I/II formulation, administered under the same conditions
Trial: 26684776
Drug: Traditional sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional sequential electrode implantation
Trial: 22237795
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural coping skills (CBCS); specific dosage and duration not mentioned.
Trial: 18343253
Drug: Topical amethocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical amethocaine gel 4%
Trial: 15809408
Drug: Medications (paroxetine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications (paroxetine, up to 50 mg daily)
Trial: 8706447
Drug: MAK 195F
RxNorm normalized name: MAK-683
DrugBank: MAK-683 (DB19205)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAK 195F (anti-TNF antibody) at 0.1 mg/kg
Trial: 8706447
Drug: MAK 195F
RxNorm normalized name: MAK-683
DrugBank: MAK-683 (DB19205)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAK 195F (anti-TNF antibody) at 0.3 mg/kg
Trial: 8706447
Drug: MAK 195F
RxNorm normalized name: MAK-683
DrugBank: MAK-683 (DB19205)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAK 195F (anti-TNF antibody) at 1.0 mg/kg
Trial: 2183879
Drug: Diazepam 0.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 0.12 mg/kg
Trial: 20348487
Drug: Subantimicrobial-dose-doxycycline (SDD)
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subantimicrobial-dose-doxycycline (SDD)
Trial: 2915293
Drug: 100 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/kg IVIG (Gamimune)
Trial: 30797491
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of EBUS‐GS and virtual bronchoscopic navigation (VBN)
Trial: 21526380
Drug: Group L
RxNorm normalized name: Blood group Lewis alpha-4-fucosyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group L (with hypointensity on MRI, n = 19)
Trial: 9121638
Drug: Transcutaneous electrical
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous electrical nerve stimulation (TENS) using 'Elektronika‐2M' apparatus with a current of 45 microA for 10‐20 min, with courses consisting of 10‐12 treatments.
Trial: 9121638
Drug: Standard methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard methods of treatment (novocaine blockade, analgesics, etc.)
Trial: 29329493
Drug: Meloxicam IV
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meloxicam IV 60 mg
Trial: 29329493
Drug: Meloxicam IV
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meloxicam IV 15 mg
Trial: 24825642
Drug: Ezetimibe (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (10 mg daily)
Trial: 24763888
Drug: Unilateral spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral spinal anesthesia with hyperbaric bupivacaine (2 ml, 0.5%)
Trial: 24763888
Drug: L1 paravertebral
RxNorm normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L1 paravertebral block combined with psoas compartment block and sciatic nerve block with bupivacaine hydrochloride (total 35 ml)
Trial: 22838231
Drug: self‐etch adhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: self‐etch adhesive (Prompt L Pop)
Trial: 22838231
Drug: no surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no surface treatment (negative control)
Trial: 19025303
Drug: Helicobacter pylori
RxNorm normalized name: HELICOBACTER PYLORI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helicobacter pylori eradication therapy (10-day course of rabeprazole, amoxicillin, and clarithromycin, followed by 20 mg of rabeprazole for 3 months)
Trial: 19025303
Drug: Control therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control therapy (20 mg of rabeprazole for 3 months)
Trial: 16861942
Drug: Steroid stop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid stop
Trial: 15636615
Drug: Control (triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (triple therapy)
Trial: 14651431
Drug: MOS-HIV health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOS-HIV health survey administered at baseline and every 3 months during 1-year follow-up
Trial: 10965646
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with no additional problem solving
Trial: 28510646
Drug: Switched DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switched DAPT (aspirin plus clopidogrel)
Trial: 28510646
Drug: Unchanged DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unchanged DAPT (aspirin plus newer P2Y12 blocker)
Trial: 25728888
Drug: L. reuteri-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. reuteri-containing lozenges
Trial: 23222534
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (FCM) - 15 mg/kg to a maximum of 1000 mg IV for NDD-CKD; 200 mg IV push for HD-CKD
Trial: 23222534
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical care (SMC) - treatment determined by the investigator, could include oral iron, IV iron or no iron
Trial: 7918139
Drug: Simendan 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simendan 1.0 mg
Trial: 7918139
Drug: Simendan 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simendan 2.0 mg
Trial: 7918139
Drug: Simendan 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simendan 5.0 mg
Trial: 7918139
Drug: Simendan 10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simendan 10.0 mg
Trial: 3451888
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg falipamil
Trial: 3451888
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of atropine
Trial: 3451888
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg cumulative dose of atropine
Trial: 3451888
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg falipamil
Trial: 3451888
Drug: ULFS 49
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ULFS 49 Cl (3 different oral doses)
Trial: 3451888
Drug: 3 X
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 X 2.5 mg p.o. (minimal effective dose)
Trial: 3451888
Drug: 3 X
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 X 5 mg p.o. (therapeutic dose)
Trial: 3451888
Drug: Side-effects typical
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Side-effects typical for 'specific bradycardic agents'
Trial: 29374674
Drug: Text message
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text message intervention providing information, motivation, and support for medication adherence, smoking cessation, healthy diet, and exercise.
Trial: 28376651
Drug: brinzolamide 1.0%/timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brinzolamide 1.0%/timolol maleate 0.5% fixed combination (BTFC)
Trial: 23232154
Drug: Ibuprofen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (10 mg/kg, max 600 mg) and Codeine (1 mg/kg, max 60 mg)
Trial: 23232154
Drug: Ibuprofen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (10 mg/kg, max 600 mg) and Placebo
Trial: 16155274
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Zn/d
Trial: 10702174
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Fe/d
Trial: 10702174
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Zn/d plus 20 mg Fe/d
Trial: 8404191
Drug: SHRZ/HR regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHRZ/HR regimen (2 months of daily streptomycin, isoniazid, rifampin, and pyrazinamide followed by 4 months of isoniazid plus rifampin)
Trial: 8404191
Drug: SHZ Cipro/H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHZ Cipro/H Cipro regimen (2 months of daily streptomycin, isoniazid, pyrazinamide, and ciprofloxacin followed by 4 months of isoniazid plus ciprofloxacin)
Trial: 27793237
Drug: Sufentanil in
RxNorm normalized name: sufentanil Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil in combination with low-dose hyperbaric bupivacaine
Trial: 16860169
Drug: ASA 325
RxNorm normalized name: ASA 325 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA 325 mg/d for 1 week, followed by ASA 100 mg/d plus clopidogrel 300 mg loading dose followed by 100 mg/d for 36 weeks (ASA+Clop group)
Trial: 16860169
Drug: ASA alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASA alone (325 mg/d for 1 week, followed by 75 mg/d for 36 weeks) (ASA group)
Trial: 12623974
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg/day, given 8 hours after awakening (time 2)
Trial: 12623974
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg/day, given before bedtime (time 3)
Trial: 8408538
Drug: Counselling intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Counselling intervention (three sessions of counselling before, during, and after the first treatment cycle)
Trial: 8408538
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (information about the treatment programme only)
Trial: 3547370
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (Control)
Trial: 31219517
Drug: mECX+L (modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mECX+L (modified ECX plus lapatinib)
Trial: 28968877
Drug: School-based and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based and village-wide preventive chemotherapy strategies (MDA) for Schistosoma mansoni
Trial: 24448262
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administration (MDA)
Trial: 23405376
Drug: Self-administered testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered testing using the Gen-Probe APTIMA Combo 2 (AC2) kit
Trial: 19706084
Drug: 1.2% clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2% clindamycin and 0.025% tretinoin (CLIN/RA) gel
Trial: 16730066
Drug: 5‐mg intralesional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐mg intralesional injection of 5‐FU weekly for 2 weeks
Trial: 16730066
Drug: 20‐mg intralesional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20‐mg intralesional injection of triamcinolone
Trial: 16730066
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (topical steroid alone)
Trial: 11744967
Drug: Intralesional triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional triamcinolone acetonide 5 mg/ml injection
Trial: 11744967
Drug: Incision, curettage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incision, curettage and intralesional triamcinolone acetonide injection
Trial: 9269010
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg sublingual triazolam
Trial: 9269010
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg oral triazolam
Trial: 8329825
Drug: Intravenous GHRH(1-29)-NH2
RxNorm normalized name: GHRH(1-44)NH2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous GHRH(1-29)-NH2 at 0.25 microgram/kg
Trial: 8329825
Drug: Intravenous GHRH(1-29)-NH2
RxNorm normalized name: GHRH(1-44)NH2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous GHRH(1-29)-NH2 at 1-2 micrograms/kg
Trial: 8329825
Drug: Intranasal GHRH(1-29)-NH2
RxNorm normalized name: GHRH(1-44)NH2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal GHRH(1-29)-NH2 at 50 micrograms/kg
Trial: 8329825
Drug: Repeated intranasal
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated intranasal GHRH(1-29)-NH2 administration
Trial: 21742946
Drug: High-soy diet
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-soy diet (2 servings of soy milk, tofu, or soy nuts, ∼50 mg of isoflavones per day)
Trial: 19356389
Drug: Roflumilast 500
RxNorm normalized name: ROFLUMILAST 500MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast 500 microg once daily (Days 1 and 15) + Erythromycin 500 mg three times daily (Days 9 - 21)
Trial: 1519573
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (40 mg/day for 4 weeks)
Trial: 6470191
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment in 21 children
Trial: 24262813
Drug: 50mg D-cycloserine
RxNorm normalized name: D-(+)-cycloserine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg D-cycloserine administered after each of ten CBT sessions
Trial: 24262813
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered after each of ten CBT sessions
Trial: 22724029
Drug: Paromomycin (PM)
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paromomycin (PM) 20 mg/kg/day for 21 days
Trial: 22724029
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate (SSG) 20 mg/kg/day for 30 days
Trial: 22724029
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PM (15 mg/kg/day) and SSG (20 mg/kg/day) for 17 days
Trial: 22724029
Drug: End of
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: End of treatment efficacy for PM
Trial: 22724029
Drug: End of
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: End of treatment efficacy for SSG & PM
Trial: 20471234
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of BDP plus montelukast (ML)
Trial: 12499890
Drug: ELAD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELAD therapy
Trial: 8915668
Drug: Idarubicin 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin 8 mg/m2/day for 5 days
Trial: 8915668
Drug: Rubidazone 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rubidazone 200 mg/m2/day for 4 days
Trial: 8915668
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose ARA-C plus m-Amsa
Trial: 8915668
Drug: Intensive consolidation
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive consolidation chemotherapy (ICC)
Trial: 1670621
Drug: Lymecycline treatment
RxNorm normalized name: lymecycline
DrugBank: Lymecycline (DB00256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymecycline treatment for 3 months
Trial: 6882615
Drug: Lipid preparation
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid preparation (Diazemuls)
Trial: 6882615
Drug: Aqueous preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous preparation (Valium)
Trial: 27483064
Drug: Liraglutide (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (1.8 mg/d via daily subcutaneous injection for 180 days)
Trial: 15175566
Drug: Intra-arterial vitamin
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial vitamin C (25 mg/min)
Trial: 15175566
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin C (1 g daily)